Navigation Links
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Date:6/30/2011

ancial assistance for co-pays, co-insurance, and treatment-related travel costs.

"These significant achievements support broad access to PROVENGE, the foundation of care for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon.  "The increased capacity and positive National Coverage Decision by CMS in conjunction with the patient assistance programs will ensure patients who may benefit from treatment with PROVENGE have increased access to it."

For information about these programs, please visit www.provenge.com or call 1-877-336-3736.

PROVENGE Indication and Safety

PROVENGE was approved by the U.S. Food and Drug Administration in April 2010 as the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The most common adverse events (incidence greater than or equal to 15%) reported in patients in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in patients in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion react
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
(Date:7/24/2014)... at the University of Delaware, is known worldwide ... engineering, environmental sustainability and electronics. , His early ... a well-defined, crystalline structure. At the atomic scale, ... zeolites can separate molecules with size differences of ... a nanometer), making them useful to the chemical ...
(Date:7/24/2014)... Research and Markets has announced the addition ... report to their offering.  http://photos.prnewswire.com/prnh/20130307/600769 ... vitro growth of plant or animal cells for several ... Cell culture is a crucial step in tissue engineering ... consumables are necessary for the in vitro production of ...
(Date:7/24/2014)... Livermore, California (PRWEB) July 24, 2014 ... due to advances in modeling lithium-ion battery storage ... could benefit from a theoretical model created at ... Rice University that predicts how carbon components ... for energy storage emphasizes the urgent need for ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2
... Company posts record quarterly revenues of $27.2 million, ... CRY ),a biomaterials, medical device and tissue ... quarter of 2008 increased 18 percent to,$27.2 million ... of 2007.,Excluding orthopaedic tissue processing revenues of $297,000 ...
... 31 Alsius Corporation,(Nasdaq: ALUS ), the ... critically ill patients, today,announced that it will hold ... results and provide a corporate update. Bill Worthen,president ... 1:30 p.m. Pacific Time,(4:30 p.m. Eastern Time) on ...
... Including Industrial ... ... Bioscience (Nasdaq:,PURE) today announced an agreement with DuraBan International ... DuraBan,s DuraClean(TM) brand., (Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO ), ...
Cached Biology Technology:CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 2CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 3CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 4CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 5CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 6CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 7CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 8CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 9CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 10CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 11Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 3PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 4
(Date:7/24/2014)... An international team of researchers led by the University ... community-led marine conservation in the Western Indian Ocean. ... ONE , point to a revolution in the management ... sites more than 11,000 km in the ... areas (MPAs) are zones of the seas and coasts ...
(Date:7/24/2014)... release is available in German . ... in Norway and they are a common sight on the ... electric cars topped the list of new vehicle registrations for ... situation in Germany, where electric vehicles claim only a small ... the roads in Germany, only a mere 8000 are electric ...
(Date:7/24/2014)... a virus living inside your gut that has gone ... by researchers at San Diego State University has found ... to a newly described virus, named crAssphage, which infects ... Bacteroidetes . This phylum of bacteria is thought ... diseases. The research appears today in Nature Communications ...
Breaking Biology News(10 mins):Western Indian Ocean communities play vital role in conservation 2Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3
... your carbon footprint, recycling more, and going green ... environmental impact? That,s the question a team of ... report their findings in a forthcoming issue of ... Management from Inderscience Publishers. The researchers ...
... July 4, chances are that sunburn will be the red glare ... there is no burn, the effects of the sun,s ultraviolet (UV) ... published in the July 2008 issue of The FASEB Journal ... is more likely to cause skin cancer than the other (UVA). ...
... the coal mine, penguins are sounding the alarm ... and the culprit isn,t only climate change, says ... pollution, depletion of fisheries and rampant coastline development ... along with Earth,s warming climate, are leading to ...
Cached Biology News:Shrinking carbon footprints 2Shrinking carbon footprints 3Sunburn alert: UVB does more damage to DNA than UVA 2Penguins setting off sirens over health of world's oceans 2Penguins setting off sirens over health of world's oceans 3Penguins setting off sirens over health of world's oceans 4
... Synaptogyrin 2 ( Abpromise ... Antigen: Synthetic ... sequence amino acids 42-57 of ... Entrez Gene ID: ...
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Biology Products: